The U.S. Supreme Court has refused to hear Biogen’s argument that its patent on the blockbuster multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) should be reinstated as part of the company’s ongoing fight with Mylan Pharmaceuticals, which has for two years marketed a generic version of the drug.
Source: Drug Industry Daily